Answer
Yes. Selected products provide either a subcutaneous abdominal injection or an intravenous infusion; the oncology team chooses the licensed formulation appropriate to the treatment plan.
Sources for this answer
- Rybrevant (amivantamab) 1600mg solution for injection — Current selected SmPCemc · Summary of Product Characteristics
- Rybrevant (amivantamab) 350mg concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics